Skip to content
DataLookout
Menu

NCT07631871

An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 15, 2026 to May 12, 2026
    • Secondary endpoints: details revised at 2 of 6 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Objective Response Rate, ORR
Timeframe: From the date of first study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 24months.

Secondary (6)

Duration of Response, DOR
Disease Control Rate, DCR
Best Overall Response, BOR
Progression-Free Survival, PFS
Overall Survival, OS
Show 1 moreShow less
Adverse Events, AEs

Arms and interventions

ZanidatamabExperimental

Zanidatamab is administered intravenously at a dose of 20 mg/kg on Day 1 of every 2-week treatment cycle.

Drugs: Zanidatamab

Sites

1 site in 1 country

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityShanghai, Shanghai Municipality, China